0838 GMT - Regulatory clearance of Novo Holdings' planned acquisition of Catalent is a significant positive for Novo Nordisk, Intron Health analyst Naresh Chouhan writes. Novo Holdings will buy U.S. contract drug maker Catalent before selling three of Catalent's production sites to Novo Nordisk. The deal has not been challenged by the Federal Trade Commission, paving the way for the deal to close in the coming days. "This is a very significant positive in our view and has both long-term and short-term upside ramifications." Intron Health believes the extra capacity will allow Novo Nordisk to boost Wegovy production and give it considerable manufacturing might which could also help deter competitors from investing in biosimilars. Shares rise 2.1% to 769.70 Danish kroner. (dominic.chopping@wsj.com)
(END) Dow Jones Newswires
December 16, 2024 03:38 ET (08:38 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。